Prednisone news

All news on Prednisone (also known as Deltasone and Meticorten): plants, production capacities, investments and involved companies.

17 June 2026

Genentech seeks FDA approval for Lunsumio VELO plus Polivy in relapsed/refractory LBCL

sBLA accepted for subcutaneous bispecific + ADC combo in relapsed/refractory large B‑cell lymphoma; FDA decision expected Feb 9, 2027.
30 January 2026

Johnson & Johnson's AKEEGA® Gets CHMP Nod for mHSPC with BRCA1/2 Mutations

CHMP backs AKEEGA® for mHSPC with BRCA1/2 mutations, showing improved progression-free survival and manageable safety profile in Phase 3 AMPLITUDE study.
16 January 2026

Genmab Reports Phase 3 Trial Results for Epcoritamab in Relapsed/Refractory DLBCL

Epcoritamab shows improved progression-free survival in Phase 3 trial for R/R DLBCL. Safety profile consistent. Further analysis and regulatory discussions planned.
12 December 2025

FDA Approves Johnson & Johnson's AKEEGA for BRCA2-Mutated Prostate Cancer

FDA approves AKEEGA for BRCA2-mutated prostate cancer, reducing disease progression by 54% and delaying symptoms by 59% in clinical trials.
6 November 2025

Johnson & Johnson's DARZALEX FASPRO®: First FDA-Approved Treatment for High-Risk Smoldering Multiple Myeloma

DARZALEX FASPRO® reduces progression risk to active multiple myeloma by 51% in high-risk patients, marking a shift in treatment strategy.
16 October 2025

Johnson & Johnson's AKEEGA® Gets FDA Priority Review for BRCA-Mutated Prostate Cancer

FDA grants Priority Review to AKEEGA® for BRCA-mutated prostate cancer, showing reduced progression risk and improved outcomes in Phase 3 study.

Who will be producing Prednisone in the future?

Find out with chemXplore Alpha

Learn more